Matches in Wikidata for { <http://www.wikidata.org/entity/Q92044160> ?p ?o ?g. }
Showing items 1 to 45 of
45
with 100 items per page.
- Q92044160 description "artículu científicu espublizáu en febreru de 2019" @default.
- Q92044160 description "scientific article published on 27 February 2019" @default.
- Q92044160 description "wetenschappelijk artikel" @default.
- Q92044160 description "наукова стаття, опублікована в лютому 2019" @default.
- Q92044160 name "Preclinical safety evaluation of the adrenomedullin-binding antibody Adrecizumab in rodents, dogs and non-human primates" @default.
- Q92044160 name "Preclinical safety evaluation of the adrenomedullin-binding antibody Adrecizumab in rodents, dogs and non-human primates" @default.
- Q92044160 type Item @default.
- Q92044160 label "Preclinical safety evaluation of the adrenomedullin-binding antibody Adrecizumab in rodents, dogs and non-human primates" @default.
- Q92044160 label "Preclinical safety evaluation of the adrenomedullin-binding antibody Adrecizumab in rodents, dogs and non-human primates" @default.
- Q92044160 prefLabel "Preclinical safety evaluation of the adrenomedullin-binding antibody Adrecizumab in rodents, dogs and non-human primates" @default.
- Q92044160 prefLabel "Preclinical safety evaluation of the adrenomedullin-binding antibody Adrecizumab in rodents, dogs and non-human primates" @default.
- Q92044160 P1433 Q92044160-C58F3404-1BF1-47B8-A527-A30DAC21D5D8 @default.
- Q92044160 P1476 Q92044160-CA5535B5-A021-4731-A8FA-AF6AA46719C1 @default.
- Q92044160 P2093 Q92044160-172E5076-C07D-4438-AF2B-29E2B990EDB8 @default.
- Q92044160 P2093 Q92044160-47EB1123-5F3C-4097-8654-692CF83D842C @default.
- Q92044160 P2093 Q92044160-9708317A-0DB2-451A-91A0-08507D5189B1 @default.
- Q92044160 P2093 Q92044160-A44EF17F-F5CB-4100-9AB6-E0548E245BF6 @default.
- Q92044160 P2093 Q92044160-CD0FEEAE-CCCD-4CE1-BC8C-425FD550E97C @default.
- Q92044160 P2093 Q92044160-D066EEDA-AAA9-4391-9ED9-627F7F796D31 @default.
- Q92044160 P2093 Q92044160-F840BD41-B123-406C-8DD9-204F12B880FF @default.
- Q92044160 P2093 Q92044160-FEF4BAD0-8B71-4064-A941-C96737054289 @default.
- Q92044160 P304 Q92044160-7A653551-D234-4F7B-8041-1DA6F1DC4915 @default.
- Q92044160 P31 Q92044160-80943FF9-E0B4-463A-B124-AD35E76A7ED4 @default.
- Q92044160 P356 Q92044160-3C33B71F-D62E-45C6-BC91-CB4CFCFC9B1A @default.
- Q92044160 P478 Q92044160-F99EF55B-795C-4ACB-A097-B8DB0BCC297A @default.
- Q92044160 P577 Q92044160-5515EC6E-2646-4B4D-B0C2-F93C1D32AA6D @default.
- Q92044160 P698 Q92044160-7B20F87C-9B92-44A9-8D6B-5652A30EC3F5 @default.
- Q92044160 P356 J.TAAP.2019.02.014 @default.
- Q92044160 P698 30822437 @default.
- Q92044160 P1433 Q2446974 @default.
- Q92044160 P1476 "Preclinical safety evaluation of the adrenomedullin-binding antibody Adrecizumab in rodents, dogs and non-human primates" @default.
- Q92044160 P2093 "Alexandre Mebazaa" @default.
- Q92044160 P2093 "Alice Blet" @default.
- Q92044160 P2093 "Andreas Bergmann" @default.
- Q92044160 P2093 "Christopher Geven" @default.
- Q92044160 P2093 "Joachim Struck" @default.
- Q92044160 P2093 "Mathias Schroedter" @default.
- Q92044160 P2093 "Matthijs Kox" @default.
- Q92044160 P2093 "Peter Pickkers" @default.
- Q92044160 P304 "1-16" @default.
- Q92044160 P31 Q13442814 @default.
- Q92044160 P356 "10.1016/J.TAAP.2019.02.014" @default.
- Q92044160 P478 "369" @default.
- Q92044160 P577 "2019-02-27T00:00:00Z" @default.
- Q92044160 P698 "30822437" @default.